CT7439 (CDK12/13i)
Advanced Solid Tumors
Phase 1Active
Key Facts
About Carrick Therapeutics
Carrick Therapeutics is an Ireland-founded, clinical-stage oncology biotech with a strategic shift to a Boston headquarters, indicating a focus on the U.S. biopharma ecosystem. Its lead asset, samuraciclib (a CDK7 inhibitor), is in multiple Phase 2 trials for HR+/HER2- advanced breast cancer, showing a combination-focused development strategy. The company also has an early-stage, first-in-class CDK12/13 inhibitor, CT7439, in Phase 1, diversifying its pipeline. Carrick operates as a private company, collaborating with major pharma partners to advance its programs.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |